Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Biofrontera (BFRI) Change in Acquisitions & Divestments (2023 - 2024)

Biofrontera has reported Change in Acquisitions & Divestments over the past 2 years, most recently at $57000.0 for Q1 2024.

For Q1 2024, Change in Acquisitions & Divestments changed N/A year-over-year to $57000.0; the TTM value through Dec 2024 reached $57000.0, changed N/A, while the annual FY2024 figure was $57000.0, 90.5% down from the prior year.
Change in Acquisitions & Divestments for Q1 2024 was $57000.0 at Biofrontera, up from $40000.0 in the prior quarter.
Over five years, Change in Acquisitions & Divestments peaked at $360000.0 in Q3 2023 and troughed at $40000.0 in Q4 2023.